The primary focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders.
For more information, please visit http://www.dsus.com.
Please see accompanying full prescribing information for AZOR and Benicar
* Creatinine clearance <40mL/min.
(1) http://www.norvasc.com -- Last accessed October 12, 2006
(2) Data are representing May 2002 - February 2006 from IMS Health.
National Prescription Audit, February 2006
(3) American Heart Association. 2004 High Blood Pressure Statistics
http://www.americanheart.org/presenter.jhtml?identifier=4621 Site
accessed 8/1/2007
(4) Data are representing May 2002 - February 2006 from IMS Health.
National Prescription Audit, February 2006
(5) National Heart, Lung and Blood Institute, High Blood Pressure Key
Points.
http://www.nhlbi.nih.gov/health/dci/Diseases/Hbp/HBP_Summary.html.
Accessed August 1, 2007
(6) American Heart Association. 2004 High Blood Pressure Statistics.
http://www.americanheart.org/presenter.jhtml?identifier=4621. Accessed
Au
'/>"/>
| SOURCE Daiichi Sankyo, Inc. Copyright©2007 PR Newswire. All rights reserved |